Category: Articles

chronic wound‐care competence in student nurses and podiatrists

The purpose of this study was to describe the level of chronic wound‐care competence among graduating student nurses and student podiatrists in comparison with that of professionals and to develop and test a new instrument (the C/WoundComp) that assesses both theoretical and practical competence in chronic wound care as well as attitudes towards wound care. The data (N = 135) were collected in 2019 from four groups (1): graduating student nurses (n = 44) (2); graduating student podiatrists (n = 28) (3); registered nurses (n = 54); and (4) podiatrists (n = 9). The data were analysed using statistical analysis. According to the results, the students’ total mean competence score was 62%. Their mean score for theoretical competence was 67%, and for practical competence, it was 52%. The students’ competence level was statistically significantly lower than that of the professionals (P < .0001), but the students showed a positive attitude towards chronic wound care. The instrument demonstrated preliminary validity and reliability, but this warrants further testing. This study provides new knowledge about student nurses’ and …. full article

———————

Summary:

This study aimed to develop and test a new assessment tool—called the C/WoundComp instrument—to evaluate both theoretical and practical competence in chronic wound care among student nurses and podiatrists. It also examined their attitudes toward chronic wound care.

Design & Participants: The study used a descriptive, comparative, and methodological approach with 135 participants:

• 44 graduating student nurses

• 28 graduating student podiatrists

• 54 registered nurses

• 9 practicing podiatrists

Key Findings:

• Students had an average competence score of 62% overall:

  • 67% in theoretical knowledge

  • 52% in practical skills

• Professionals scored significantly higher than students.

• Students showed positive attitudes toward chronic wound care despite limited competence.

• The C/WoundComp instrument showed initial reliability and validity for assessing wound-care competence.

Conclusion: Graduating students lack sufficient theoretical and practical knowledge in chronic wound care, highlighting the need to strengthen wound-care education. The C/WoundComp tool could help evaluate and improve competence in this critical area of healthcare.

The authors:

• Emilia Kielo-Viljamaa, PhD, RN: Dr. Kielo-Viljamaa is a Senior Lecturer at Novia University of Applied Sciences, Faculty of Health and Welfare, in Vaasa, Finland. She also serves as a Postdoctoral Researcher at the University of Turku’s Department of Nursing Science. Her research focuses on nursing education and wound care competence. ​ResearchGate

• Riitta Suhonen, PhD, RN: Dr. Suhonen is affiliated with the Department of Nursing Science at the University of Turku, Turku University Hospital, and the Welfare Division of the City of Turku in Finland. She has an extensive background in nursing science and education. ​PubMed

• Maarit Ahtiala: Associated with Turku University Hospital in Finland, contributing to research in nursing and healthcare. ​PubMed

• Terhi Kolari: Affiliated with the Department of Biostatistics at the University of Turku, focusing on statistical analysis in medical research. ​PubMed

• Jouko Katajisto: Part of the Department of Mathematics and Statistics at the University of Turku, specializing in statistical methodologies. ​PubMed

• Leena Salminen, PhD, RN: Connected with the Department of Nursing Science at the University of Turku, with research interests in nursing education and professional competence. ​PubMed+1ResearchGate+1

• Minna Stolt, PhD, RN: Also from the Department of Nursing Science at the University of Turku, Dr. Stolt’s research includes nursing education and wound care. ​PubMed

​

Society of Tissue Viability Conference 2025
Solving skin and wound challenges together

30 April – 01 May 2025
LIFE Centre, Wapping Road, Bradford BD3 0EQ

Want to attend?
We are delighted to offer several FREE conference registrations (travel / accommodation bursaries are ‘sold out’) to attend our conference. Link below to find out more and apply now.

Call for abstracts
Are you doing some great work in research? Do you have a case study or product evaluation that you would like to present? Then consider submitting to #SoTV2025! The call for abstracts is now open! Find out more below. Closing 28 February, 2025. Submissions now closed. Thank you to everyone that has submitted – we will notify you of the results soon

Get in touch
If you have any questions, email hello@societyoftissueviability.org

A wound heals by progression through various stages of inflammation, granulation tissue synthesis, collagen deposition and maturation, and epithelization.¹ The majority of acute wounds follow this organized pattern to achieve structural and functional stability. However, some acute wounds with large raw areas progress into chronic wounds refractory to conventional treatments. The presence of bacteria in significant numbers is one important reason a wound may not proceed through the healing trajectory …. full article

Speaker:

A Multimethod Study

Diabetes-related lower extremity amputations (LEAs) are among the most devastating complications of diabetes, profoundly impacting physical, psychological, and social well-being. The Diabetes-Related Extremity Amputation Depression and Distress (DREADD) study examines the emotional and psychological consequences of amputation in diabetic individuals, employing a multimethod approach to capture the full spectrum of patient experiences.

The Psychological Toll of Amputation

Individuals who undergo amputations due to diabetes-related complications, such as diabetic foot ulcers and peripheral artery disease (PAD), often experience profound emotional distress. Depression, anxiety, and post-traumatic stress are common, exacerbated by a loss of mobility, independence, and altered self-identity. Many struggle with feelings of grief, shame, and social isolation, impacting their overall quality of life and mental health.

A Multimethod Approach

The DREADD study employs both qualitative and quantitative research methods to explore these psychological impacts. Surveys and standardized depression scales, such as the Patient Health Questionnaire-9 (PHQ-9), are used to measure depression severity, while structured interviews provide insights into personal struggles, coping mechanisms, and unmet psychological needs. Additionally, biometric data, including heart rate variability and cortisol levels, offer physiological indicators of chronic stress and emotional dysregulation.

Findings and Implications for Care

Preliminary findings suggest that nearly half of patients experience moderate to severe depression post-amputation, with many lacking adequate mental health support. Factors such as poor social support, financial strain, and preexisting mental health conditions contribute to worse outcomes. The study underscores the need for integrated care models that address both physical and psychological rehabilitation, including peer support groups, counseling services, and cognitive behavioral therapy (CBT) to improve patient adaptation and emotional resilience.

By highlighting the critical intersection between diabetes, amputation, and mental health, the DREADD study aims to reshape post-amputation care, advocating for holistic interventions that go beyond wound healing to address the profound psychological distress faced by affected individuals.

by Claire Kowalick, University of Texas Health Science Center at San Antonio

Texas has one of the highest rates of diabetes in the country, with more than 2.7 million Texans diagnosed with the condition. About one in six people in San Antonio have type 2 diabetes, and a third of residents are prediabetic, according to the American Diabetes Association.

Type 2 diabetes is a chronic condition in which the body cannot produce enough insulin or use insulin properly and, if left uncontrolled, can lead to high blood sugar, heart disease and kidney failure. It also predisposes people to foot ulcers, of which almost 50% become infected, subsequently leading to hospitalization and potentially amputation of part of the foot or a lower limb … full article

related:

Texas has one of the highest rates of diabetes in the country, with more than 2.7 million Texans diagnosed with the condition. This epidemic has significant implications for healthcare systems, particularly in the management of complications like diabetic foot ulcers (DFUs). In San Antonio, where approximately one in six residents has type 2 diabetes and a third of the population is prediabetic, the risk of developing DFUs is alarmingly high.

Diabetic foot ulcers result from a combination of neuropathy, poor circulation, and impaired immune response, all of which are common in individuals with long-standing diabetes. Without proper intervention, these ulcers can progress to severe infections, leading to hospitalizations, amputations, and increased mortality rates. Given the high prevalence of diabetes in Texas, hospitals and wound care centers face mounting challenges in treating and preventing these wounds effectively.

The economic burden of DFUs is also substantial. Studies indicate that treating a single DFU can cost tens of thousands of dollars, with the total cost of diabetic foot care in the U.S. exceeding billions annually. In areas like San Antonio, where diabetes rates are disproportionately high, local healthcare facilities must prioritize specialized wound care services, early detection, and preventive measures such as total contact casting (TCC) to offload pressure from wounds and enhance healing.

Community-wide initiatives are essential to combat this growing crisis. Increasing awareness about proper foot care, expanding access to podiatric and wound care specialists, and implementing preventive strategies—such as routine screenings for neuropathy and peripheral artery disease (PAD)—can significantly reduce the incidence and severity of DFUs. Additionally, addressing social determinants of health, such as limited access to quality healthcare, lower socioeconomic status, and dietary challenges, is crucial in mitigating the long-term consequences of diabetes-related foot complications.

As Texas continues to grapple with rising diabetes rates, proactive intervention and innovative wound care solutions will be key in preventing DFUs and improving patient outcomes.

Background. Martorell hypertensive ischemic leg ulcer (HYTILU) is a chronic, hard-to-heal wound linked to hypertension. This study explores nanofat grafting as a regenerative alternative to traditional skin grafting for improved healing and patient outcomes. Objective. To explore the efficacy of nanofat grafting in the management of HYTILU and compare it with skin grafting. Materials and Methods. This was a retrospective single-center pilot study involving 23 patients with HYTILU treated with adipose-derived stromal cells (adipose-derived stromal cells/nanofat). The primary outcomes were ulcer healing rate, pain reduction, and improvements in quality of life, as measured by SCAR-Q (a scar quality of life questionnaire) and the Vancouver Scar Scale, over a period of 6 months posttreatment. Results. This study revealed a significant decrease in ulcer size from an initial mean of 39.69 cm² to complete healing, with an average healing time of 4.65 months. The mean visual analog scale pain scores significantly decreased from an initial score of 5.87 to 0.39 at 3 months …. read more

Kathleen D. Schaum, MS

Medicare coverage for distinct types of wounds/ulcers has received attention for many years. Because the theme of this issue of Advances in Skin & Wound Care is pressure injuries (PIs), this article reviews whether Medicare covers certain technologies and procedures for PIs.

DEBRIDEMENT

Most Medicare Administrative Contractors (MACs) have a Local Coverage Determination (LCD) and Local Coverage Article (LCA) that address the coverage guidelines for debridement of all types of wounds/ulcers, including PIs. Some MACs have a separate debridement LCD/LCA, whereas others include debridement coverage guidelines within their LCD/LCA related to wound care. Readers should check their MAC’s LCDs, which do not limit debridement to distinct wound types. However, their LCDs/LCAs have similar coverage guidelines that include, but are not limited to, documentation of:

• History and physical examination with an initial wound description, location, measurements, and response to prior treatment (if applicable).
• Identification of wound location, size, depth, and stage (supported by a drawing or photograph of the wound).
• Clinical documentation of diagnosis or symptoms to justify services.
• Current progress notes including measurable signs of healing as well as causes of delayed wound healing or modifications to the treatment plan.
• Documentation of the wound’s characteristics (e.g., dimensions, necrotic tissue presence, tissue removed, degree of epithelialization) before and after debridement.
• Operative note or procedure note for debridement services, including descriptions of tissue debrided, wound measurements, and pre-/post-debridement wound assessments.
• Plan of care containing treatment goals and physician follow-up.read full article

Kathleen D. Schaum, MS, is a healthcare reimbursement expert specializing in wound care, durable medical equipment (DME), and Medicare coverage policies. She is the president and founder of Kathleen D. Schaum & Associates, a consulting firm focused on payment strategies for healthcare providers and manufacturers. Schaum is a frequent author and speaker on reimbursement-related topics in wound care and medical technology.

Johns Hopkins University has announced plans to eliminate over 2,200 jobs following the Trump administration’s decision to cut $800 million in grants previously allocated by the U.S. Agency for International Development (USAID). This reduction represents the largest layoff in the university’s history, affecting 247 positions within the United States and 1,975 positions across 44 countries.

The job cuts will impact several key divisions of the university, including the Bloomberg School of Public Health, the School of Medicine, and the affiliated nonprofit organization Jhpiego, which focuses on international health initiatives. The university expressed deep concern over the funding termination, stating that it forces them to wind down critical work both domestically and internationally.

This development is part of a broader trend affecting higher education institutions across the United States. Several universities, including Harvard, the Massachusetts Institute of Technology, and the University of California, San Diego, have implemented hiring freezes and other cost-saving measures in response to federal funding uncertainties. These financial strains threaten the academic and research integrity of these institutions and pose risks to job growth in higher education.

The reduction in USAID funding is expected to have significant implications for global health initiatives, particularly those targeting infectious diseases and women’s health in low-income countries. Johns Hopkins University and other research institutions anticipate further financial challenges and have initiated legal actions against the proposed budget reductions.

As the largest private employer in Maryland and Baltimore, Johns Hopkins University’s decision to cut over 2,000 jobs underscores the real-world impact of federal funding policies on employment and public health research.

Alton R. Johnson Jr., DPM, DABPM, FACPM, FASPS, CWSP
John Steinberg, DPM, FACFAS

In this insightful episode, Dr. Alton Johnson, Dr. John Steinberg, and host Brian discuss the often-overlooked phase of wound care: life after healing. The conversation shifts from the traditional focus on simply closing wounds to a broader perspective that emphasizes function, long-term remission, and patient education.

Dr. Johnson shares his journey as a young physician who initially believed healing was the final step, only to realize that patients frequently return due to recurring wounds. He highlights the importance of educating patients on easing back into daily activities and managing their healed wounds like a condition in remission.

Dr. Steinberg builds on this by emphasizing function over limb salvage, noting that saving a limb without restoring mobility can leave patients unable to regain independence. He recalls advice from his colleague, Dr. Chris Attinger, who stressed that preventing wounds from returning is just as crucial as healing them.

The discussion underscores the need for early planning in the healing process, ensuring patients have the right prosthetics, orthotics, and footwear in place before their wounds fully close. By shifting the focus from simply healing wounds to optimizing long-term mobility and quality of life, this episode offers valuable insights for clinicians, caregivers, and patients alike.

Listen

This event will be held at 7:30pm, 26th February 2025.

Presented by Paulo Ramos, RN, (Nurse Specialist at ULS Póvoa de Varzim / Vila do Conde, USF Corino de Andrade, Portugal. Certified wound care educator. Board Member of the Portuguese Wound Care Association and a EWMA Council Member. Member of the EWMA Working Groups of AMS and Compression Therapy. Chair of EWMA Education Comittee).

Register interest

by Caroline Fife, M.D. | Feb 19, 2025

A taxonomy code is a unique 10-character identifier that specifies a practitioner’s (physician or nurse practitioner) classification and specialization. This code is required when applying for a National Provider Identifier (NPI), which is necessary for billing Medicare. NPI applications are processed through the National Plan & Provider Enumeration System (NPPES). Clinicians are expected to select the taxonomy code that best represents their provider type, classification, or specialization. However, I am not aware of any regulations mandating that a practitioner be board-certified in the specialty associated with their chosen taxonomy code.
https://carolinefifemd.com/2025/02/19/new-taxonomy-codes-for-wound-care-practitioners/

Recognizing Excellence in Wound Care Research and Practice

The Journal of Wound Care (JWC) Awards 2025 took place on Friday, 14th February 2025, at the prestigious Imperial War Museum in London. This annual event celebrates excellence in research, innovative practices, and outstanding contributions across the wound care community.

This year’s winners and finalists represent the dedication and expertise driving advancements in wound care, from pioneering clinical interventions to transformative research and education. Their work continues to push the boundaries of patient care, setting new standards for the field.

Congratulations to all those recognized for their achievements!

For a full list of winners and highlights from the event, visit the JWC Awards website.

Frank and Lizzie sit down with Mark Overcash, RN, WCSP, a seasoned wound care specialist with over 25 years of experience and the National Sales Manager at MPM Medical. In this insightful conversation, Mark shares the latest industry trends, key findings from professional surveys, and the increasing demand for multifunctional, cost-effective wound dressings.

MPM Medical, a leader in advanced wound care since 1992, has consistently prioritized feedback from healthcare professionals to develop innovative solutions. Their newest product, TriSAP, is a silicone-based, silver-infused, super-absorbent dressing designed to tackle exudate management, infection control, and reimbursement challenges.

Join us for an in-depth discussion on how TriSAP is shaping the future of wound care and revolutionizing patient treatment!

https://www.hmpgloballearningnetwork.com/site/wounds/videos/frank-lizzie-show-episode-27-multifunctional-dressings-future-doing-more-less

Mark Overcash, RN, CWSP, is a seasoned wound care specialist with over 25 years of experience. He began his nursing career in 1997 and transitioned to medical sales focusing on wound care in 2000. In 2023, Mark joined MPM Medical, and within a year, he was promoted to National Sales Manager.

He has been instrumental in promoting MPM Medical’s latest dressing, TriSAP, which addresses exudate management, infection control, and supports reimbursement needs.

Mark actively engages with healthcare professionals at industry events, such as the Desert Foot conference, to share advanced solutions for diabetic and venous stasis ulcers.

ANAHEIM, Calif., July 5, 2023 /PRNewswire/ — Histologics LLC attended “WOCNext” in Las Vegas last June 4-6th to exhibit its novel debridement and wound biopsy fabric-curettage devices including for the first time, the SoftBiopsy®+D device. Over 1M cases by clinicians used Kylon® devices for colposcopic biopsy and curettage in the USA, in nearly every clinical setting www.histologics.com. The hooked medical (Kylon®) fabric tipped brushes gently remove and can trap tissue for biopsy for histology or microbiology. The debridement may be performed at a lighter “hygiene” level, extending all the way to “excisional” surgical methods when the brush array converts to micro-curettes if the fabric is pressed firmly and wiped or twisted into tissue.

Kylon® Fabric Debridement and Biopsy : Video Simulation

The cause of some wounds not to heal includes biofilm, and the Kylon® fabric devices can be used to obtain true tangential biopsy samples from the debrided wound base for lab testing.  This is commonly done with the SoftBiopsy® product, solely used for biopsy that is sent to a laboratory. Histologics recently released SoftBiopsy®+D, a more versatile and durable version for clinicians, that can sustain longer procedure time for wound debridement as well as biopsy.

We have previously demonstrated the value of our Soft K-Rette® device to debride and sample crevice wounds, and Soft K-Cot® deployed on the finger for “Compassionate Debridement at Your Fingertips®”.

The scope of practice of most physicians and nurse clinicians vary from basic wound care to the most advanced surgical procedures where necrotic wound tissue must be mechanically or surgically removed.  Advanced and basic wound care providers include many specialties in health care and procedures occur in clinics, hospitals, homes, facilities and other settings. Some providers that shy away from regular debridement (necessary to heal wounds) due to the invasive nature of the scalpel and sharp curette would be willing to clean wounds using the gentle  Kylon® devices.

Please visit our wound care website to request free samples at www.histologicwc.com,  or contact Lily Ramos at histologicswc@gmail.com, Toll Free:  888-235-2275.

SOURCE Histologics LLC

Former Healogics CEO Brings Deep Wound Care Industry Experience to MolecuLight’s
Rapidly Growing Business

TORONTO, July 6, 2023 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated, pathogenic bacterial loads in and around wounds, is pleased to announce the appointment of David Bassin to its Board of Directors as an Independent Board Member.

David Bassin brings a wealth of expertise and experience in the healthcare industry, particularly in the field of wound care. As the founder of GIO Advisory LLC, he has provided invaluable advisory services to numerous companies and private equity firms based on his extensive background in healthcare, spanning pharmaceutical/device, payer, and provider services. Most recently, Bassin served as the CEO of Healogics, the foremost provider of wound care services in the US, operating over 630 wound care centers and 300 providers. During his tenure, he successfully restructured and refocused the business, resulting in strong earnings growth prior to his transition into advisory services. Prior to his role as CEO, Bassin served as the CFO of Healogics, contributing to the company’s financial growth and success. Bassin’s impressive career also includes significant roles in other healthcare organizations. He served as the CFO of eviCore Healthcare, Inc., where he oversaw multiple dividend recapitalizations and facilitated a merger with the company’s largest competitor, leading to the creation of a company with over 3,000 employees. Additionally, Bassin held the position of CFO at InVentiv Health, Inc., a provider of services to pharmaceutical companies, where he successfully managed a high-growth company and orchestrated a go-private transaction valued at over $1 billion and delivered a significant premium to its shareholders.

“We are thrilled to welcome David Bassin to the MolecuLight Board of Directors,” said Anil Amlani, CEO of MolecuLight. “His extensive experience in optimizing and scaling organizations across the healthcare industry, particularly in wound care, will be invaluable to MolecuLight as we continue to expand our global presence. Our MolecuLight devices have already become indispensable tools in wound assessment and real-time decision-making for thousands of clinicians worldwide. David’s expertise will greatly support our mission to meet the increasing global demand for our innovative wound care diagnostics and establish them as the gold standard in the field.”

David Bassin expressed his excitement about joining MolecuLight’s Board of Directors, stating, “There are over 6.5 million patients living with wounds.  As an industry, we need to continue to develop new solutions that improve wound care treatment effectiveness and efficiency.  With a global drive to improve outcomes, reduce costs, and minimize antibiotic usage, MolecuLight’s point-of-care devices have demonstrated their ability to effectively address these critical clinical needs. I am deeply impressed by the organization, the technology’s alignment with market demands, and the significant market traction they have achieved. I am eager to contribute to their growth and help them achieve their ambitious goals.”

MolecuLight’s groundbreaking i:X® and DX™ imaging devices are the only FDA-cleared and CE and Health Canada approved devices for the real-time detection of elevated bacterial burden in wounds. Supported by over 80 peer-reviewed publications involving 2,600 patients, these devices are widely utilized by leading wound care facilities worldwide.

MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s commercial devices, which include the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, are point-of-care handheld imaging devices for the real-time detection and localization of bacterial load in wounds and digital wound measurement. MolecuLight procedures performed in the United States benefit from an available reimbursement pathway which includes two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other global markets with relevant unmet needs in food safety, consumer cosmetics and other key industrial markets.

For more information, contact:

Rob Sandler 
Chief Marketing Officer
MolecuLight Inc.
T. +1.647.362.4684
rsandler@moleculight.com
www.moleculight.com

Image:

• Download: https://moleculight.box.com/s/91awddbrynrybjwkeyyabgcbz8fxk9xh

SOURCE MolecuLight

Led by Susa Ventures and Sozo Ventures, the funding will be used to transform the $45B wound and ostomy care industry by bringing on-demand experts to more patients and providers in need via telehealth and in-person visits

The Wound Company, a multi-channel on-demand wound and ostomy care delivery company that improves patient outcomes, today announced its launch from stealth with $4.25M in seed funding from Susa Ventures and Sozo Ventures. The funding will be used to expand the company’s national footprint, hire top talent, and to continue improving health outcomes in the most cost-effective way possible while bringing dignity to the over 13 million people in need of improved wound and ostomy care.

Why Wound Care Matters

The US is experiencing an amputation epidemic due to diabetic foot ulcers and other serious wounds. Despite medical advancements, Americans are amputating double the number of limbs today than during the Civil War. About 50% of lower extremity amputations would have been preventable if patients with type 2 diabetes and foot ulcers had access to better healthcare. This issue is one of the problems The Wound Company is solving for.

Often providers need more wound care expertise or, due to understaffing, don’t have time to offer comprehensive care continuously, leaving patients to figure it out on their own. This leads to wound care patients returning to the hospital due to improper wound care. But it can be prevented.

“The wound and ostomy care industry is broken,” said Nima Ahmadi, founder and CEO of The Wound Company. “It’s operating in the fee-for-service world, which pushes expensive procedures and products that help the bottom line, but don’t impact outcomes for the patient. We’re paid to heal wounds with continuous care and, in doing so, save money for health plans and at-risk providers.”

Enter The Wound Company

The Wound Company aims to fix the broken space of wound and ostomy care by using predictive analytics and multi-channel communications to deliver the right wound and ostomy care to the right patient in the right channel at the right time. The tech connects patients and providers to wound and ostomy experts virtually or via in-person visits to ensure they have top-tier care.

“The Wound Company’s innovative technologies have the potential to save health plans billions of dollars and transform the patient experience,” says Susa Ventures Investor Derick En’Wezoh. “With a dedicated team of highly experienced experts, a strong vision, and a passion for improving healthcare outcomes, this tech will save lives.”

The platform also offers clinical reporting, customer data integration, and workflow automation to make care delivery as painless as possible for providers.

While in stealth, The Wound Company has already partnered with health plans, health systems, home care providers, hospice providers, and patients, with significant results to date:

• A potential 15-20% reduction in the total cost of care for wound and ostomy patients for payers
• Up to 50% savings on supplies per patient for home and hospice care providers
• 60% of patients demonstrated progressive healing week after week
• 90% of Stage I/II pressure ulcers resolved without advancing to a higher stage
• 100% of ostomy patients have a predictable pouching system and reduced chance of ER visits or readmissions

“Our blend of virtual and in-person services provided by passionate experts in wound care helps people heal quickly, safely, and with the dignity they deserve while helping to alleviate the pressure on overworked healthcare professionals,” said Chief Medical Officer Sanford Roberts.

The Wound Company is open to partnerships with health plans, at-risk providers, home health providers, and hospice care providers. For more information, visit www.thewound.co.

About The Wound Company

The Wound Company is a Minneapolis-based technology company dedicated to advancing wound and ostomy care. The company uses proprietary technology to connect providers with experienced and certified wound care specialists who can care for patients virtually or via in-person visits. The Wound Company partners with health plans, home care companies, and providers to bring dignity to patients with wounds and ostomies while increasing positive patient outcomes.

This article was originally published here

David G. Armstrong, DPM, PhD, is an internationally recognized leader in the field of podiatric surgery, diabetic foot, limb preservation, and wound healing.

DALLAS, TX, USA, June 12, 2023/EINPresswire.com/ — Venturis Therapeutics, Inc. (“VT” or the “Company”) announces that David G Armstrong, DPM MD PhD will assume the role of senior academic advisor for the surgeon board. This agreement was consummated following a review of the Company’s scientific and commercial opportunities.

Armstrong is the foremost expert in diabetic limb preservation and is recognized worldwide with a huge following through his prodigious authorship and lectures on diabetic limb salvage. This affiliation will further enhance the diabetic wound program and clinical research trials being undertaken by VT, and will improve the visibility of the Company dramatically among all those in the greater biotech wound healing community.

ABOUT VENTURIS THERAPEUTICS
Venturis Therapeutics, Inc. is a biopharmaceutical company developing protein drug candidates to address diseases such as severe coronary heart disease, diabetic wounds, peripheral artery disease, erectile dysfunction, stroke, and spinal disk disease. The active pharmaceutical ingredient (“API”) in our drug candidates is FGF-1, a human protein that stimulates the growth of new blood vessels, thereby increasing the blood supply to ischemic organs and tissues.

FORWARD LOOKING STATEMENTS
This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of VT drug candidates, market acceptance of VT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage, and financial performance. Additionally, until VT is cash flow positive from operations, the Company is dependent upon raising capital to fund its operations and meet its obligations as they come due. There can be no assurance that VT will be able to raise the necessary capital when needed.

Amy Gordon
Venturis Therapeutics Inc
+1 972-904-2029
email us here

Dr. David G Armstrong The 18th Malvern Diabetic Foot Conference Future of Wound Treatment

NEXA NPWT System Launched in the USA

OCEANSIDE, Calif., June 7, 2023 /PRNewswire/ — AOTI Inc, the global leader in multi-modality topical wound oxygen, announced exciting news from ongoing WOCNext conference in Las Vegas, Nevada, where their game changing NEXA Negative Pressure Wound Therapy (NPWT) system made its official USA debut.

The unique NEXA NPWT system is an incredibly flexible platform that is simple to use, silent, portable and affordable. NEXA seamlessly combines the simplicity of disposable NPWT with the performance features of more traditional durable NPWT technology platforms.

Dr. Mike Griffiths, CEO and President of AOTI commented; “Releasing the innovative NEXA NPWT platform in the USA is a major milestone for the company that will allow clinicians, payers, and patients alike to experience much improved performance at significantly lower cost. With NEXA, we have reimagined how NPWT should function.

Its addition to our portfolio only further enhances our mission of helping all people with chronic conditions get back to living their lives to the fullest.”

AOTI’s unique NEXA NPWT and Topical Wound Oxygen (TWO2) therapy are unlike any other treatment approaches. NEXA provided unrivaled flexibility and performance in a portable NPWT system. TWO2 is the only device that provides a multimodality treatment, combining higher pressure oxygen delivery with non-contact cyclical compression and humidity, in a therapeutic applied by the patient at home. This patented approach has been demonstrated in numerous Randomized Controlled Trial (RCT) and Real World Evidence (RWE) studies to not only heal chronic wounds at a far higher rate, but perhaps more importantly, keep them closed longer term, thereby reducing unnecessary hospitalizations and amputations.^{1, 2}

¹ Multinational, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen (TWO2) Therapy in the Treatment of Chronic Diabetic Foot Ulcers; The TWO2 Study. Robert G. Frykberg et al, Diabetics Care 2020; 43:616-624. https://doi.org/10.2337/dc19-0476.

² Reduced Hospitalizations and Amputations in Patients with Diabetic Foot Ulcers Treated with Cyclical Pressurized Topical Wound Oxygen Therapy: Real-World Outcomes; Jessica Izhakoff Yellin, et al; Advances in Wound Care 2022; http://doi.org/10.1089/wound.2021.0118

About AOTI

AOTI is a privately-owned company based in Oceanside, California USA and Galway, Ireland that provides innovative solutions to resolve severe and chronic wounds worldwide. Our mission is to help all people with chronic conditions get back to living their lives to the fullest. We do this by enhancing access to care, improving quality of life and advancing health equity. 
Our products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. Our patented Topical Wound Oxygen (TWO2) at home therapy is clinically proven to deliver Sustained Wound Healing that reduces both Amputations and Hospitalizations, So Life Can Get Back to Normal.

For more information see: www.aotinc.net

Contact:
Dr. Mike Griffiths
CEO & President
360322@email4pr.com
(760) 672 1920

SOURCE AOTI Inc.

BOULDER, CO / ACCESSWIRE / June 8, 2023 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn^® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, dermatology, and eye, oral and nasal care, today announced a new application for intraoperative pulse lavage irrigation treatment, which can replace commonly used IV bags in a variety of surgical procedures.

Sonoma developed this new application of its wound care technology in response to an unmet need for a non-toxic irrigation solution that can prevent infection and improve healing time. The intraoperative pulse lavage container is designed to be used in combination with a pulse lavage irrigation device, or flush gun, for abdominal, laparoscopic, orthopedic, and periprosthetic procedures. This product replaces commonly used non-antimicrobial saline and aggressive rinsing solutions with safe and effective Microcyn^® Technology. Microcyn^® Technology assists in the reduction of microorganisms, is non-toxic, and has regenerative properties, making it critical in preventing infection and promoting wound healing. Sonoma’s pulse lavage container is also cost competitive with IV bags, the current standard of care.

Sonoma developed the intraoperative pulse lavage irrigation treatment in close collaboration with the medical community and Sonoma’s existing distribution partners in Europe and expects this new application will be met with wide acceptance. Sonoma is now accepting orders for the pulse lavage irrigation treatment solution, which is expected to be ready for commercial use in Europe in September 2023. Sonoma anticipates commercial launch in the U.S. in 2024.

“Sonoma continues to lead in the innovation of products that improve outcomes for people with wounds or injuries or who are needing surgery. We continue to see increased demand for our wound care products in Europe, and we are excited to expand our offerings to include this next generation irrigation solution to help people heal faster following surgery,” said Amy Trombly, CEO of Sonoma Pharmaceuticals.

For more information, or to pre-order our pulse lavage irrigation treatment solution in Europe, please contact info.europe@sonomapharma.com.

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, animal health care and non-toxic disinfectants. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin, and oxygenates the cells in the area treated, assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “company”). These forward-looking statements are identified by the use of words such as “continue,” “develop,” “anticipate,” “expect” and “expand,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company’s products will not be as large as expected, the company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company’s cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™ and Microcyn^® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:

Sonoma Pharmaceuticals, Inc.

ir@sonomapharmaceuticals.com

SOURCE: Sonoma Pharmaceuticals, Inc.

Swift’s AI-powered wound imaging technology shown to improve quality of care and costs to manage complex patients

June 01, 2023 09:00 AM Eastern Daylight Time
TORONTO–(BUSINESS WIRE)–Swift Medical, a digital health technology company focused on improving clinical and economic outcomes in wound care, today announced proven outcomes from more than 20 million wound assessments captured with Swift’s leading, AI-powered wound care platform. Deployed in nearly 4,000 healthcare facilities across North America, Swift’s technology has been shown to speed up wound healing by 37%, reduce wound prevalence and hospitalizations by 35% and 14%, respectively, and reduce hospital length of stay by 62%.

“We are proud to share the incredible impact our technology is having on the millions of patients living with wounds – one of today’s most expensive and overlooked threats to patients and our overall healthcare system”

Tweet this
“We are proud to share the incredible impact our technology is having on the millions of patients living with wounds – one of today’s most expensive and overlooked threats to patients and our overall healthcare system,” said Brian Litten, CEO of Swift Medical. “These outcomes demonstrate the impact of having the most powerful wound image dataset in the world and its ability to deliver high quality wound care with reduced costs.”

The Swift Skin & Wound mobile application enables any mobile device to be equipped with AI-powered imaging capabilities to capture clinically validated, high-precision 3D images, measurements, and other clinical data. The imaging captured at the point of care enables real-time, at-risk patient monitoring, proactive decision-making, and remote wound consultations, reducing the time and cost spent evaluating wounds to create a more efficient wound care experience for both clinicians and patients.

Today, more people suffer from chronic wounds than those with breast cancer, colon cancer, lung cancer, and leukemia combined. Despite this costly, growing problem, the current standard of care is outdated and highly inaccurate. Clinicians typically receive less than 10 hours of formal education and rely on paper rulers for measurements and cotton swabs for depth assessment. This inefficient and ineffective approach is both painful for patients and leads to poor diagnostic accuracy, prolonged healing, and inappropriate selection of therapies, putting patients at greater risk for readmission, longer lengths of stay and higher care costs.

With its advanced analytics and proven outcomes, Swift is now poised to partner with health plans and risk-bearing providers to deliver high quality, value-based wound care at scale.

About Swift Medical

Swift Medical is the global leader in digital wound care. We are headquartered in Toronto, with operations expanding across the U.S. and Canada. Our mission is to make empathy-driven wound care ubiquitous through AI-powered diagnostic technology. We are the trusted wound technology partner of more than 4,000 healthcare facilities in North America across the continuum of care. Our solutions empower healthcare providers to deliver standardized, accessible and equitable wound care for every patient – with advanced, high-precision imaging, compliant documentation, clinical analytics and remote care. To learn more about Swift Medical, visit us at www.swiftmedical.com.

Contacts
Media

David Mannion
416-303-8020
david.mannion@swiftmedical.com